DK0674512T3 - Anvendelse af riluzol ved behandling af neurologiske skader knyttet til traumer - Google Patents

Anvendelse af riluzol ved behandling af neurologiske skader knyttet til traumer

Info

Publication number: DK0674512T3
Authority: DK; Denmark
Prior art keywords: riluzole; treatment; pct; trauma; damage associated
Prior art date: 1992-12-16

Application number

DK94902019.2T

Other languages

English (en)

Inventor

Jean-Marie Stutzmann

Adam Doble

Erik Louvel

Jeremy Pratt

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-16

Filing date

1993-12-10

Publication date

1998-05-25

1993-12-10 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1998-05-25 Application granted granted Critical

1998-05-25 Publication of DK0674512T3 publication Critical patent/DK0674512T3/da

Links

FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 2
208000014674 injury Diseases 0.000 title abstract 2
230000000926 neurological effect Effects 0.000 title abstract 2
229960004181 riluzole Drugs 0.000 title abstract 2
230000008733 trauma Effects 0.000 title 1
208000020339 Spinal injury Diseases 0.000 abstract 1
230000003902 lesion Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000008736 traumatic injury Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Thiazole And Isothizaole Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Data Exchanges In Wide-Area Networks (AREA)
Crystals, And After-Treatments Of Crystals (AREA)

DK94902019.2T 1992-12-16 1993-12-10 Anvendelse af riluzol ved behandling af neurologiske skader knyttet til traumer DK0674512T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9215148A FR2699077B1 (fr)	1992-12-16	1992-12-16	Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.

Publications (1)

Publication Number	Publication Date
DK0674512T3 true DK0674512T3 (da)	1998-05-25

Family

ID=9436652

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94902019.2T DK0674512T3 (da)	1992-12-16	1993-12-10	Anvendelse af riluzol ved behandling af neurologiske skader knyttet til traumer

Country Status (23)

Country	Link
US (1)	US5830907A (da)
EP (3)	EP0674512B1 (da)
JP (3)	JP3712239B2 (da)
KR (3)	KR100298808B1 (da)
AT (1)	ATE164067T1 (da)
AU (3)	AU678795B2 (da)
CA (3)	CA2151601A1 (da)
CZ (3)	CZ154695A3 (da)
DE (1)	DE69317578T2 (da)
DK (1)	DK0674512T3 (da)
ES (1)	ES2113635T3 (da)
FR (1)	FR2699077B1 (da)
GR (1)	GR3026403T3 (da)
HU (3)	HUT71839A (da)
IL (3)	IL108051A (da)
MX (3)	MX9307883A (da)
NO (3)	NO952228L (da)
PL (3)	PL309348A1 (da)
RU (1)	RU2142800C1 (da)
SK (3)	SK279759B6 (da)
UA (1)	UA41906C2 (da)
WO (3)	WO1994013298A1 (da)
ZA (3)	ZA939401B (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2700117B1 (fr) *	1993-01-07	1995-02-03	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
GB9424766D0 (en) *	1994-12-07	1995-02-08	Wellcome Found	Pharmaceutical composition
FR2733684B1 (fr)	1995-05-03	1997-05-30	Cird Galderma	Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
GB9512854D0 (en) *	1995-06-23	1995-08-23	Wellcome Found	Novel formulation
US20020022056A1 (en)	1997-02-14	2002-02-21	Burkhard Schlutermann	Oxacarbazepine film-coated tablets
CO4920215A1 (es) *	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
DK1032575T3 (da)	1997-09-05	2003-10-20	Glaxo Group Ltd	2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor
GB9808015D0 (en) *	1998-04-15	1998-06-17	United Medical And Dental Scho	Protection of the nervous system from the effects of inflammatory disease
US6150423A (en) *	1998-10-15	2000-11-21	Phoenix Scientific, Inc.	Propofol-based anesthetic and method of making same
FR2787028B1 (fr)	1998-12-15	2002-10-18	Aventis Pharma Sa	Utilisation du riluzole dans le traitement des traumatismes acoustiques
JP2002543131A (ja) *	1999-04-29	2002-12-17	センターナショナルデラレシェルシェサイエンティフィック（シーエヌアールエス）	大動脈クロスクランピングが原因の虚血性脊髄損傷の防止方法
GB9925962D0 (en) *	1999-11-02	1999-12-29	Novartis Ag	Organic compounds
GB9930058D0 (en) *	1999-12-20	2000-02-09	Novartis Ag	Organic compounds
RU2240113C1 (ru) *	2003-01-23	2004-11-20	Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова	Способ экстренной медикаментозной помощи при острой травме спинного мозга
US20060252745A1 (en)	2005-05-06	2006-11-09	Almeida Jose L D	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP1924326B1 (en)	2005-08-25	2016-10-12	Steven Michael Weiss	Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
GB0700773D0 (en)	2007-01-15	2007-02-21	Portela & Ca Sa	Drug therapies
WO2014037832A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167985A1 (en) *	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological disorders
US9399634B2 (en)	2012-05-07	2016-07-26	Cellix Bio Private Limited	Compositions and methods for the treatment of depression
WO2013168021A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013168025A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en)	2012-05-08	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological degenerative disorders
WO2013167992A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en)	2012-05-08	2016-12-20	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of parkinson's disease
WO2013168012A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
US9273061B2 (en)	2012-05-10	2016-03-01	Cellix Bio Private Limited	Compositions and methods for the treatment of chronic pain
WO2013168004A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of fibromyalgia pain
US9321775B2 (en)	2012-05-10	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of moderate to severe pain
WO2013168000A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of severe pain
WO2013167997A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
US9499527B2 (en)	2012-05-10	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168005A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168015A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neurologic diseases
WO2013168016A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
WO2013168002A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological conditions
WO2013167999A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurologic diseases
NZ701832A (en)	2012-05-23	2016-08-26	Cellix Bio Private Ltd	Compositions and methods for treatment of inflammatory bowel disease
JP2015518854A (ja)	2012-05-23	2015-07-06	セリックスビオプライヴェートリミテッド	多発性硬化症の治療のための組成物および方法
WO2013175344A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en)	2012-05-23	2016-11-15	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
AU2013264820A1 (en)	2012-05-23	2014-11-27	Cellixbio Private Limited	Compositions and methods for treatment of mucositis
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en)	2012-08-03	2014-02-06	Mahesh Kandula	Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en)	2012-09-08	2014-12-30	Cellix Bio Private Ltd	Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en)	2013-06-04	2015-12-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
NZ736131A (en)	2014-09-26	2019-04-26	Cellix Bio Private Ltd	Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es)	2014-09-29	2020-12-16	Cellix Bio Private Ltd	Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja)	2014-10-27	2019-08-21	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
WO2016088132A1 (en)	2014-12-01	2016-06-09	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en)	2015-01-06	2017-08-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of inflammation and pain
CA2999367C (en)	2015-09-23	2023-09-26	Xw Laboratories Inc.	Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
EP3601235B1 (en) *	2017-03-30	2026-03-04	XWPharma Ltd.	Bicyclic heteroaryl derivatives, preparation and therapeutic uses thereof
US10322114B2 (en)	2017-07-31	2019-06-18	Above And Beyond Nb, Llc	Formulation of a riluzole solution with beta-cyclodextrins
WO2019108594A1 (en) *	2017-11-28	2019-06-06	University Of Houston System	Liquid formulations of riluzole for oral and intravenous use
CN114042070A (zh)	2018-09-30	2022-02-15	凯瑞康宁生物工程（武汉）有限公司	作为神经元组胺受体-3拮抗剂的化合物及其用途
TWI899126B (zh)	2019-12-20	2025-10-01	香港商凱瑞康寧有限公司	４－纈胺醯氧基丁酸的合成方法
CN115038432B (zh)	2020-06-18	2023-12-26	凯瑞康宁生物工程（武汉）有限公司	水溶性活性药物成分的控制释放制粒
AU2021293941B2 (en)	2020-06-18	2024-03-28	XWPharma Ltd.	Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en)	2020-07-24	2022-01-27	XWPharma Ltd.	Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en)	2020-10-05	2023-08-16	XWPharma Ltd.	Modified release compositions of a gamma-hydroxybutyric acid derivative
JP2024511991A (ja)	2021-03-19	2024-03-18	エックスダブリューファーマリミテッド	ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
WO2025216887A1 (en)	2024-04-11	2025-10-16	Dow Global Technologies Llc	High internal phase emulsion
US12605388B2 (en)	2024-09-25	2026-04-21	Azurity Pharmaceuticals Ireland Limited	Lamotrigine salts, co-crystals, and compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK153787C (da) *	1979-06-01	1989-01-16	Wellcome Found	Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
FR2492258A1 (fr) *	1980-10-17	1982-04-23	Pharmindustrie	Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) *	1980-10-17	1984-02-14	Ciba-Geigy Corporation	Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) *	1986-05-30	1986-07-02	Wellcome Found	Triazine salt
US4826860A (en) *	1987-03-16	1989-05-02	Warner-Lambert Company	Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) *	1988-01-25	1990-04-17	Warner-Lambert Company	Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
US5240948A (en) *	1989-12-13	1993-08-31	Rhone-Poulenc Rorer Pharmaceuticals Inc.	3-(3-alkylthiopropyl)benzothiazoline derivatives, their preparation and the medicament containing them
GB9012312D0 (en) *	1990-06-01	1990-07-18	Wellcome Found	Pharmacologically active cns compounds
WO1992014697A1 (en) *	1991-02-08	1992-09-03	Cambridge Neuroscience, Inc.	Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
FR2688138B1 (fr) *	1992-03-06	1995-05-05	Rhone Poulenc Rorer Sa	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

1992
- 1992-12-16 FR FR9215148A patent/FR2699077B1/fr not_active Expired - Fee Related
1993
- 1993-12-10 AU AU56540/94A patent/AU678795B2/en not_active Ceased
- 1993-12-10 CA CA002151601A patent/CA2151601A1/fr not_active Abandoned
- 1993-12-10 CZ CZ951546A patent/CZ154695A3/cs unknown
- 1993-12-10 CZ CZ951545A patent/CZ284420B6/cs not_active IP Right Cessation
- 1993-12-10 CA CA002151604A patent/CA2151604C/fr not_active Expired - Fee Related
- 1993-12-10 JP JP51388094A patent/JP3712239B2/ja not_active Expired - Fee Related
- 1993-12-10 KR KR1019950702460A patent/KR100298808B1/ko not_active Expired - Fee Related
- 1993-12-10 DK DK94902019.2T patent/DK0674512T3/da active
- 1993-12-10 PL PL93309348A patent/PL309348A1/xx unknown
- 1993-12-10 WO PCT/FR1993/001228 patent/WO1994013298A1/fr not_active Ceased
- 1993-12-10 JP JP6513878A patent/JPH08504428A/ja active Pending
- 1993-12-10 SK SK786-95A patent/SK279759B6/sk not_active IP Right Cessation
- 1993-12-10 PL PL93309346A patent/PL309346A1/xx unknown
- 1993-12-10 SK SK785-95A patent/SK78595A3/sk unknown
- 1993-12-10 EP EP94902019A patent/EP0674512B1/fr not_active Expired - Lifetime
- 1993-12-10 SK SK787-95A patent/SK78795A3/sk unknown
- 1993-12-10 JP JP6513879A patent/JPH08504429A/ja active Pending
- 1993-12-10 HU HU9501752A patent/HUT71839A/hu unknown
- 1993-12-10 WO PCT/FR1993/001227 patent/WO1994013296A1/fr not_active Ceased
- 1993-12-10 KR KR1019950702459A patent/KR950703968A/ko not_active Withdrawn
- 1993-12-10 CA CA002151603A patent/CA2151603A1/fr not_active Abandoned
- 1993-12-10 PL PL93309347A patent/PL309347A1/xx unknown
- 1993-12-10 ES ES94902019T patent/ES2113635T3/es not_active Expired - Lifetime
- 1993-12-10 EP EP94902802A patent/EP0674518A1/fr not_active Withdrawn
- 1993-12-10 DE DE69317578T patent/DE69317578T2/de not_active Expired - Lifetime
- 1993-12-10 AU AU57020/94A patent/AU5702094A/en not_active Abandoned
- 1993-12-10 WO PCT/FR1993/001229 patent/WO1994013288A1/fr not_active Ceased
- 1993-12-10 KR KR1019950702458A patent/KR950703965A/ko not_active Withdrawn
- 1993-12-10 EP EP94902018A patent/EP0674520A1/fr not_active Ceased
- 1993-12-10 CZ CZ951547A patent/CZ154795A3/cs unknown
- 1993-12-10 AU AU56539/94A patent/AU5653994A/en not_active Abandoned
- 1993-12-10 RU RU95114405A patent/RU2142800C1/ru not_active IP Right Cessation
- 1993-12-10 AT AT94902019T patent/ATE164067T1/de active
- 1993-12-10 UA UA95062798A patent/UA41906C2/uk unknown
- 1993-12-10 HU HU9501753A patent/HUT71812A/hu unknown
- 1993-12-10 US US08/424,529 patent/US5830907A/en not_active Expired - Lifetime
- 1993-12-10 HU HU9501751A patent/HU217133B/hu not_active IP Right Cessation
- 1993-12-13 MX MX9307883A patent/MX9307883A/es unknown
- 1993-12-13 MX MX9307882A patent/MX9307882A/es not_active Application Discontinuation
- 1993-12-13 MX MX9307884A patent/MX9307884A/es unknown
- 1993-12-15 ZA ZA939401A patent/ZA939401B/xx unknown
- 1993-12-15 ZA ZA939400A patent/ZA939400B/xx unknown
- 1993-12-15 ZA ZA939399A patent/ZA939399B/xx unknown
- 1993-12-16 IL IL10805193A patent/IL108051A/en not_active IP Right Cessation
- 1993-12-16 IL IL10805293A patent/IL108052A0/xx unknown
- 1993-12-16 IL IL10805393A patent/IL108053A0/xx unknown
1995
- 1995-06-06 NO NO952228A patent/NO952228L/no unknown
- 1995-06-06 NO NO952229A patent/NO952229L/no unknown
- 1995-06-06 NO NO952230A patent/NO307027B1/no not_active IP Right Cessation
1998
- 1998-03-19 GR GR970403094T patent/GR3026403T3/el unknown

Also Published As

Publication number	Publication date
WO1994013296A1 (fr)	1994-06-23
EP0674520A1 (fr)	1995-10-04
FR2699077A1 (fr)	1994-06-17
JPH08504428A (ja)	1996-05-14
NO952228D0 (no)	1995-06-06
FR2699077B1 (fr)	1995-01-13
SK78595A3 (en)	1996-05-08
HU217133B (hu)	1999-11-29
HU9501751D0 (en)	1995-08-28
CA2151604C (fr)	2005-09-20
EP0674512A1 (fr)	1995-10-04
HUT71839A (en)	1996-02-28
DE69317578D1 (de)	1998-04-23
WO1994013288A1 (fr)	1994-06-23
UA41906C2 (uk)	2001-10-15
ZA939400B (en)	1994-08-19
WO1994013298A1 (fr)	1994-06-23
HUT71812A (en)	1996-02-28
NO952229D0 (no)	1995-06-06
PL309347A1 (en)	1995-10-02
ZA939401B (en)	1994-08-19
JP3712239B2 (ja)	2005-11-02
SK279759B6 (sk)	1999-03-12
NO307027B1 (no)	2000-01-31
ZA939399B (en)	1994-08-22
KR950703965A (ko)	1995-11-17
NO952228L (no)	1995-06-06
CA2151603A1 (fr)	1994-06-23
EP0674512B1 (fr)	1998-03-18
ATE164067T1 (de)	1998-04-15
CZ154795A3 (en)	1995-11-15
US5830907A (en)	1998-11-03
CA2151601A1 (fr)	1994-06-23
CZ154695A3 (en)	1995-11-15
KR950703954A (ko)	1995-11-17
AU5653994A (en)	1994-07-04
CA2151604A1 (fr)	1994-06-23
NO952230L (no)	1995-06-06
PL309348A1 (en)	1995-10-02
PL309346A1 (en)	1995-10-02
DE69317578T2 (de)	1998-07-23
MX9307884A (es)	1994-06-30
HU9501753D0 (en)	1995-08-28
IL108051A0 (en)	1994-04-12
JPH08504430A (ja)	1996-05-14
IL108051A (en)	1999-05-09
GR3026403T3 (en)	1998-06-30
SK78695A3 (en)	1996-05-08
AU5654094A (en)	1994-07-04
HU9501752D0 (en)	1995-08-28
AU678795B2 (en)	1997-06-12
HUT71814A (en)	1996-02-28
AU5702094A (en)	1994-07-04
CZ284420B6 (cs)	1998-11-11
MX9307883A (es)	1994-06-30
NO952229L (no)	1995-06-06
ES2113635T3 (es)	1998-05-01
NO952230D0 (no)	1995-06-06
EP0674518A1 (fr)	1995-10-04
IL108052A0 (en)	1994-04-12
IL108053A0 (en)	1994-04-12
SK78795A3 (en)	1996-05-08
RU2142800C1 (ru)	1999-12-20
JPH08504429A (ja)	1996-05-14
KR950703968A (ko)	1995-11-17
CZ154595A3 (en)	1995-11-15
KR100298808B1 (ko)	2001-11-22
MX9307882A (es)	1994-06-30

Publication	Publication Date	Title
DK0674512T3 (da)	1998-05-25	Anvendelse af riluzol ved behandling af neurologiske skader knyttet til traumer
KR960701051A (ko)	1996-02-24	이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
IL108285A0 (en)	1994-04-12	Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes
ATE152628T1 (de)	1997-05-15	Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
NO984965D0 (no)	1998-10-23	Komponent B som cicatrisant
ZA9427B (en)	1994-08-11	Use of riluzole for promoting restoration following radiation